Antimicrobial Susceptibility of Staphylococcus Isolates from the Skin of Patients with Diarrhea-Predominant Irritable Bowel Syndrome Treated with Repeat Courses of Rifaximin.
作者信息
DuPont Herbert L, Wolf Ray A, Israel Robert J, Pimentel Mark
机构信息
The University of Texas School of Public Health, Kelsey Research Foundation, Baylor College of Medicine, Baylor St. Luke's Medical Center, Houston, Texas, USA
Salix Pharmaceuticals, Raleigh, North Carolina, USA.
出版信息
Antimicrob Agents Chemother. 2016 Dec 27;61(1). doi: 10.1128/AAC.02165-16. Print 2017 Jan.
Abstract
摘要
相似文献
1
Antimicrobial Susceptibility of Staphylococcus Isolates from the Skin of Patients with Diarrhea-Predominant Irritable Bowel Syndrome Treated with Repeat Courses of Rifaximin.接受利福昔明重复疗程治疗的腹泻型肠易激综合征患者皮肤分离出的葡萄球菌的抗菌药敏性
Antimicrob Agents Chemother. 2016 Dec 27;61(1). doi: 10.1128/AAC.02165-16. Print 2017 Jan.
2
Pharmacokinetic drug evaluation of rifaximin for treatment of diarrhea-predominant irritable bowel syndrome.利福昔明治疗腹泻型肠易激综合征的药物动力学药物评价。
Expert Opin Drug Metab Toxicol. 2018 Jul;14(7):753-760. doi: 10.1080/17425255.2018.1488964. Epub 2018 Jun 22.
3
Rifaximin (Xifaxan) for irritable bowel syndrome with diarrhea.
Med Lett Drugs Ther. 2015 Aug 3;57(1474):109-11.
4
Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity.利福昔明重复治疗肠易激综合征：粪便微生物对抗生素的敏感性无临床显著变化。
Dig Dis Sci. 2017 Sep;62(9):2455-2463. doi: 10.1007/s10620-017-4598-7. Epub 2017 Jun 6.
5
Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome.利福昔明重复治疗对腹泻型肠易激综合征患者安全有效。
Gastroenterology. 2016 Dec;151(6):1113-1121. doi: 10.1053/j.gastro.2016.08.003. Epub 2016 Aug 13.
6
Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome.利福昔明用于治疗腹泻型肠易激综合征。
Expert Opin Pharmacother. 2015 Mar;16(4):607-15. doi: 10.1517/14656566.2015.1007951. Epub 2015 Feb 1.
7
Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation.利福昔明治疗肠易激综合征——药物安全性评估
Expert Opin Drug Saf. 2016 Jul;15(7):983-91. doi: 10.1080/14740338.2016.1186639. Epub 2016 May 23.
8
Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.腹泻型肠易激综合征管理的最新进展：聚焦利福昔明和埃索美拉嗪。 （注：原文中Eluxadoline应为Eluxadroline，中文通用名是埃索美拉嗪，是一种治疗腹泻型肠易激综合征的药物。这里按照正确名称翻译了，原译文可能存在拼写错误。）
Pharmacotherapy. 2016 Mar;36(3):300-16. doi: 10.1002/phar.1712. Epub 2016 Mar 11.
9
Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome.利福昔明用于治疗腹泻型肠易激综合征。
Expert Rev Gastroenterol Hepatol. 2016;10(4):431-42. doi: 10.1586/17474124.2016.1140571. Epub 2016 Mar 1.
10
Rifaximin for irritable bowel syndrome without constipation.利福昔明用于治疗非便秘型肠易激综合征。
N Engl J Med. 2011 Apr 14;364(15):1467; author reply 1468. doi: 10.1056/NEJMc1101839.
引用本文的文献
1
The potential for development of clinically relevant microbial resistance to rifaximin-α: a narrative review.利福昔明-α相关的临床微生物耐药性的发展潜力：叙事性综述。
Clin Microbiol Rev. 2023 Dec 20;36(4):e0003923. doi: 10.1128/cmr.00039-23. Epub 2023 Nov 16.
2
Mechanism of action and therapeutic benefit of rifaximin in patients with irritable bowel syndrome: a narrative review.利福昔明在肠易激综合征患者中的作用机制及治疗益处：一项叙述性综述
Therap Adv Gastroenterol. 2020 Jan 23;13:1756284819897531. doi: 10.1177/1756284819897531. eCollection 2020.
3
Management of irritable bowel syndrome with diarrhea: a review of nonpharmacological and pharmacological interventions.腹泻型肠易激综合征的管理：非药物和药物干预综述
Therap Adv Gastroenterol. 2019 Oct 4;12:1756284819878950. doi: 10.1177/1756284819878950. eCollection 2019.
4
Pathophysiology of NSAID-Associated Intestinal Lesions in the Rat: Luminal Bacteria and Mucosal Inflammation as Targets for Prevention.大鼠非甾体抗炎药相关性肠道病变的病理生理学：以管腔细菌和黏膜炎症作为预防靶点
Front Pharmacol. 2018 Nov 29;9:1340. doi: 10.3389/fphar.2018.01340. eCollection 2018.
5
Short-course therapy for diarrhea-predominant irritable bowel syndrome: understanding the mechanism, impact on gut microbiota, and safety and tolerability of rifaximin.腹泻型肠易激综合征的短程疗法：了解利福昔明的作用机制、对肠道微生物群的影响以及安全性和耐受性
Clin Exp Gastroenterol. 2018 Sep 24;11:335-345. doi: 10.2147/CEG.S167031. eCollection 2018.
6
Rifampin Resistance in Staphylococci after Rifaximin Intake for Surgical Prophylaxis in Elective Colorectal Surgery.利福昔明用于择期结直肠手术的外科预防后葡萄球菌的利福平耐药性。
Antimicrob Agents Chemother. 2018 Nov 26;62(12). doi: 10.1128/AAC.01353-18. Print 2018 Dec.
7
Review article: an analysis of safety profiles of treatments for diarrhoea-predominant irritable bowel syndrome.综述文章：腹泻型肠易激综合征治疗安全性分析。
Aliment Pharmacol Ther. 2018 Oct;48(8):817-830. doi: 10.1111/apt.14948. Epub 2018 Sep 7.
8
Repeat treatment with rifaximin improves irritable bowel syndrome-related quality of life: a secondary analysis of a randomized, double-blind, placebo-controlled trial.利福昔明重复治疗可改善肠易激综合征相关生活质量：一项随机、双盲、安慰剂对照试验的二次分析
Therap Adv Gastroenterol. 2017 Sep;10(9):689-699. doi: 10.1177/1756283X17726087. Epub 2017 Sep 11.
本文引用的文献
1
Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome.利福昔明重复治疗对腹泻型肠易激综合征患者安全有效。
Gastroenterology. 2016 Dec;151(6):1113-1121. doi: 10.1053/j.gastro.2016.08.003. Epub 2016 Aug 13.
2
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.从对涉及肠道菌群的病理学潜在效用角度研究利福昔明及对照药物对536株厌氧肠道细菌的体外活性。
Antimicrob Agents Chemother. 2009 Jan;53(1):281-6. doi: 10.1128/AAC.00441-08. Epub 2008 Oct 27.
Zotero 插件